Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tas-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 18/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tas-115 SCHEMBL29853531 | 1.00 | MET (1.00) | METKDRPDGFRAPDGFRBAXL | |
| Tas-115 SCHEMBL16782348 | 0.97 | MET (0.94) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL23677959 | 0.93 | MET (0.87) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL1132734 | 0.93 | MET (0.88) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL1132173 | 0.93 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL20248763 | 0.92 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| Hydrochloric Acid SCHEMBL1132605 | 0.92 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL25129971 | 0.92 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL23761102 | 0.92 | MET (0.85) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL1132166 | 0.92 | MET (0.85) | METKDRPDGFRAPDGFRBAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684806-A1 | FAP-TARGETED ANTIBODY-DRUG CONJUGATES | Oncomatryx Biopharma, S.L. (ES) | 2026-01-28 | — | — | EP | claimed |
| EP-4653019-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| CN-119792395-A | Pharmaceutical composition and application thereof | 上海黄海制药有限责任公司 | 2025-04-11 | — | — | CN | claimed |
| US-12144892-B2 | Pharmaceutical composition | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-11-19 | — | — | US | claimed |
| EP-3583943-B1 | PHARMACEUTICAL COMPOSITION | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-09-18 | — | — | EP | claimed |
| EP-4419909-A1 | 3D CANCER CELLS | University of Sunderland (GB) | 2024-08-28 | — | — | EP | claimed |
| WO-2024153229-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | 江苏恒瑞医药股份有限公司 | 2024-07-25 | — | — | WO | claimed |
| CN-117137915-A | Pharmaceutical composition | 大鹏药品工业株式会社 | 2023-12-01 | — | — | CN | claimed |
| CN-110312511-B | Pharmaceutical composition | 大鹏药品工业株式会社 | 2023-10-27 | — | — | CN | claimed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-20180289690-A1 | THERAPEUTIC AGENT FOR FIBROSIS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | claimed |
| US-20180161317-A1 | MESYLIC ACID SALT OF ACYLTHIOUREA COMPOUND, CRYSTAL OF THE SAME, AND PROCESS FOR PRODUCING THESE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | claimed |
| EP-3315131-A1 | THERAPEUTIC AGENT FOR FIBROSIS | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | claimed |
| EP-3290405-A1 | MESYLIC ACID SALT OF ACYLTHIOUREA COMPOUND, CRYSTAL THEREOF, AND PRODUCTION PROCESSES THEREFOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | claimed |
| US-20140378409-A1 | EFFECT POTENTIATOR FOR ANTITUMOR AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | claimed |
| EP-2799070-A1 | EFFECT POTENTIATOR FOR ANTITUMOR AGENTS | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-11-05 | — | — | EP | claimed |
| EP-2287155-B1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | claimed |
| US-8304427-B2 | Acylthiourea compound or salt thereof, and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | claimed |
| EP-2287155-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | claimed |
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | MET, HGF, STAT6 | MET 1/4885KDR 296/4885PDGFRA 201/4885 |
| US-20140378409-A1 | EFFECT POTENTIATOR FOR ANTITUMOR AGENTS | MCL1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | MET 579/4885KDR 3629/4885PDGFRA 1230/4885 |
| US-12144892-B2 | Pharmaceutical composition | SI, SLC10A2, TPMT | MET 3238/4885KDR 4544/4885PDGFRA 2023/4885 |
| US-20180161317-A1 | MESYLIC ACID SALT OF ACYLTHIOUREA COMPOUND, CRYSTAL OF THE SAME, AND PROCESS FOR PRODUCING THESE | TPMT, AADAC, APRT | MET 639/4885KDR 4479/4885PDGFRA 743/4885 |
| US-20180289690-A1 | THERAPEUTIC AGENT FOR FIBROSIS | MMP1, MMP8, COL2A1 | MET 1113/4885KDR 4396/4885PDGFRA 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.